Vaxart (VXRT) Proxy filing summary

Executive summary

• Urges shareholders to vote for all six director nominees at the July 16, 2026 Annual Meeting.

• Highlights strategic actions to advance the vaccine pipeline and value creation.

• Emphasizes the company's focus on oral recombinant vaccines for COVID-19, norovirus, influenza, and HPV.

• Notes recent capital raises and partnerships to support continued development.

• Cautions about forward-looking statements and associated risks.

Voting matters and shareholder proposals

• Shareholders are asked to vote for all six board nominees on the WHITE proxy card.

• The board withdrew a reverse split proposal after shareholder feedback.

• Multiple settlement offers were made to dissident shareholders to resolve the proxy contest.

Board of directors and corporate governance

• The board has substantial expertise in biotech, vaccine development, and regulatory affairs.

• Two new independent directors were added in the last 18 months, reducing average tenure to 2.3 years.

• W. Mark Watson was appointed Lead Independent Director in 2025 to strengthen oversight.

• The board maintains active dialogue with shareholders and is responsive to feedback.